News
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Median Technologies and PASREL-Imagerie Join Forces to Deliver Smart Imaging Biomarkers Supporting the Development of New Oncology Drugs in Precision Medicine
Regulatory News:
Median Technologies (Paris:ALMDT) and PASREL-Imagerie, announce today the signing of an agreement to deliver cutting-edge imaging biomarkers for the development of new oncology
Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Median Technologies to Speak at the IASLC 2023 North America Conference on Lung Cancer (NACLC), Dec. 1-3, Chicago, IL, USA, with two Presentations
Regulatory News:
Median Technologies (Paris:ALMDT) announced today that the Company will be presenting two scientific posters at the 2023 North America Conference on Lung Cancer (NACLC) being
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s
Median Technologies Selected for Support Under the French Government's ETIncelles Program
Regulatory News:
Median Technologies (Paris:ALMDT) is proud to have been chosen to join the ETIncelles scheme, an initiative created by the President of the French Republic, which aims to help
Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231126347438/en/
Median Technologies (Paris:ALMDT) today unveils a
Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the
Median Technologies to Speak at the Radiological Society of North America 2023 Annual Meeting, Nov. 26 - 30, Chicago, IL, USA
Regulatory News:
Median Technologies (ALMDT) announced today that the Company will be speaking and presenting at the world’s largest medical imaging conference, the Radiological Society of North
BILENDI: Revenues for 3rd quarter 2023 up +1.8% (+2.0% at constant exchange rates)
ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
Sensorion to Participate in the Jefferies London Healthcare Conference and McDermott Will & Emery’s Life Sciences Symposium
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and
Median Technologies Reports 2023 Half-year Results and Business Indicators for the Third Quarter of 2023
Regulatory News:
Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within
First Results of Median Technologies’ iBiopsy® HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress (Oct 20-24, 2023, Madrid, Spain)
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) announces today that the first results of its iBiopsy® HCC detection AI model developed on the PHELICAR clinical data registry will
Median Technologies’ Global iCRO Team to participate in the 2023 ESMO Congress, Oct 20 – 24, 2023, Madrid, Spain
Regulatory News:
Median Technologies (ALMDT:PA) announced today that the Company will be participating in the prestigious 2023 European Society for Medical Oncology (ESMO) Congress, set to take
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
BILENDI: Bilendi awarded by the Market Research Society for its worldwide research project with Harvard and Zurich Universities
BILENDI: Bilendi now provides innovative solutions to interview niche audiences worldwide
Sensorion Announces the Availability of Its Financial Report for the 1st Half of 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within
Sensorion Announces Webconference on September 25, 2023, and its Participation in Upcoming Investor Conferences in October 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within
Sensorion Reports 2023 First Half Results
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within